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of transplant-related coronary artery disease and die while 
awaiting a donor organ. The third group of deaths includes 
patients with transplant-related coronary artery disease who 
are ineligible for retransplantation on the basis of our exclu-
sion criteria. 
Finally, as you mentioned, our most significant association 
with transplant-related coronary artery disease are immuno-
logic factors such as an earlier onset of high-grade rejection 
and an increased cumulative frequency of high-grade rejec-
tion. We have not observed any relationship between 
ischemic injury and transplant -related coronary artery dis-
ease. However. in our experience, the incidence of ischemic 
injury on the first cardiac biopsy is relatively uncommon, in 
the range of 5% of first cardiac biopsies. 
Dr Robert W. Emery (Minneapolis, Minn). I am curious 
about the fact that you found ischemic cardiomyopathy to be 
a risk factor for retransplantation because you removed the 
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end-organ. This would imply an ongoing, underlying, un-
treated disease process. Do you think that the new heart will 
be subject to this ongoing process? Do we need to look fur-
ther into why patients with ischemic cardiomyopathy have 
retransplantation, or are there other comorbid risk factors that 
would contribute to problems with retransplantation? 
Dr John. Thank you, Dr Emery. The concern regarding 
heart transplantation for ischemic cardiomyopathy is that 
even though the end-organ is replaced, the basic risk factors 
for the primary pathogenesis of the disease, namely, athero-
sclerosis. persists. It is important to be aggressive with mod-
ification of ri sk factors for atherosclerosis after heart trans-
plantation, such as the avoidance of cigarette smoking, 
control of hypertension. and the use of lipid-lowering agents. 
Otherwise. progressive atherosclerosis. both in the retrans-
planted heart and in other organs such as the kidney, will con-
tribute to a relatively poorer survival. 
In the October 1998 issue of the Journal, in the article by Alvarez and associates titled 
"Rhabdomyolysis After Coronary Artery Bypass Grafting in a Patient Receiving Simvastatin" 
(1998; 116:654-5) the name of the second author was misspelled. The correct spelling of the name is 
T. 1. Rawdanowicz, MBBS. 
